8:25 am Chair’s Opening Remarks

Better Recapitulating Age-Related Disease to Bridge the Gap Between Animal & Human Studies

8:30 am Benefits & Opportunities of Using Human 3D Spheroid Primary Cell Models to Improve Translational Research & Interventions

  • Birgit Schilling Professor & Director Proteomics Center, Buck Institute for Research on Aging


  • Advantages of high-throughput screening 3D-tissue models derived from aged human donors: working with human primary cells spheroids
  • Relevance of more native micro-environments of 3D cell spheroids forming 3-dimensional pellets for therapeutic intervention testing
  • Opportunities & integration – development of human model systems that better mirror human disease susceptibility

9:00 am Advantages & Disadvantages of Using IN VITRO Reductionist Models for Age-Related Disease & Their Prospects for Modeling Complex Mechanisms of Aging


  • Can IN VITRO models faithfully recapitulate in vivo age-related disease?
  • Aging isn’t a clinical disease
  • The diversity of approaches in vitro, how do we compare?

Delineating Current & Future Therapeutic Modalities to Illuminate the Windows of Opportunity for Age-Related Disease Drug Discovery

9:30 am Panel Discussion: Deliberating the Next Steps Forward Towards Enhancing Transferability from Animal Models to Humans


  • Are the hallmarks of aging applicable to humans when observations have come from model organisms?
  • A Dog is a Man’s best friend: Should we look at dogs next?

10:00 am Simultaneously Targeting Inflammation & Oxidative Injury: Delaying Aging While Fighting Age-Related Illnesses & Immune-Mediated Diseases Such as Sarcopenia & Rheumatoid Arthritis


  • Both inflammation and oxidative stress can contribute to the aging process and age-related diseases, and blocking both may be a synergistic approach to slowing aging while simultaneously preserving healthy function
  • MYMD-1, an orally delivered, small molecule therapeutic for the treatment of inflammatory and autoimmune disorders, including age-related diseases including sarcopenia and rheumatoid arthritis
  • MYMD-1 selectively blocks adaptive but not innate immunity, and inhibits the production of free radicals
  • Currently completing a Phase 2 study in Sarcopenia and will commence a Phase 2 in Rheumatoid Arthritis in later in 2023

10:30 am Structured Networking


This session is a great opportunity to introduce yourself to the attendees that you would like to have more in-depth conversations with. This session is the ideal opportunity to get face-to face time with many of the brightest minds working in the cardiovascular field and establish meaningful business relationships

11:00 am Morning Break & Networking

11:30 am Harnessing the Immune System to Ablate Senescent Cells and Treat Age Related Diseases


  • Unlocking the potential benefits of senolytics to promote healthy human aging
  • Tapping into other possible advances including the identification of individuals at a higher risk for age-related disease

11:30 am Towards the Defeat of Cholesterol and Reversal of Cholesterol-Driven Conditions

  • Reason Chief Executive Officer & Co-Founder, Repair Biotechnologies


  • Localized excess cholesterol in tissue drives some of the most widespread human conditions with the greatest unmet need
  • NASH cannot be reversed by the present standard of care and progress to cirrhosis and liver cancer
  • Unravelling a new technology that can directly and safely clear excess cholesterol, making earnest inroads into curing these conditions

12:00 pm Disrupting Disease Landscapes: AI-Driven Insights from Large Biomedical Datasets


  • AI’s impact on complex disease research: Discuss how artificial intelligence and advanced machine learning techniques transform human health, genetic, and rich phenotypic data analysis
  • Shifting to longitudinal studies: Explore the integration of AI and dynamic systems theory into very large models of human health to enable comprehensive causal inference, understanding of time scales, reversibility, and intricate relation between aging and complex diseases
  • Connecting molecular biology and disease understanding: Examine the role of real-world, longitudinal data in deepening our understanding of complex diseases and informing treatment strategies
  • Advancing drug discovery and development: Assess the prospects for novel therapeutic targets, emerging therapeutic modalities, and generative chemistrydriven pipelines that lead to groundbreaking drugs and improved healthcare

12:30 pm Harnessing the Immune System to Ablate Senescent Cells and Treat Age Related Diseases


  • Discovering the underlying immune mechanism responsible for the ablation of senescent cells
  • Using small molecule immune agonists to eliminate senescent cells and resolve multiple classes of disease

1:00 pm Lunch Break & Networking

2:00 pm Brain Drain: Ameliorating Brain Aging with CSF Management

  • Doug Ethell Chief Executive Officer & Founder, Leucadia Therapeutics


  • Disruptions in CSF egress contribute to Alzheimer’s disease and brain aging
  • Revealing the development of an implantable device to prevent CSF egress
  • Uncovering this year’s plans for clinical trials

2:30 pm Reversing Cell Aging in Age-Related CNS & Cardiovascular Disease: Where Are We Now?


  • The role of cell aging in CNS and CV disease
  • Optimal points of clinical intervention and delivery systems including LNPs and AAVs
  • Clinical trials, regulatory hurdles, and protocols

3:00 pm Turning Back the Clock to Treat, Reverse & Prevent Age-Related Disease


  • Rationale and implications of partial epigenetic reprogramming
  • New data from a non-human primate model of NAION – progressing the evidence for partial reprogramming with the transcription factors OSK
  • Potential to repair the body’s ability to recycle unwanted proteins with CMA activators to treat and reverse age-related disease

3:30 pm Update on NaNots: A Subtractive Method of Treating Age-Related Disease Including Cancer & Inflammatory Disease


  • Latest results in collaboration with Mayo Clinic
  • Planned clinical trials in cancer and sepsis
  • Implications for longevity interventions

4:00 pm Afternoon Break & Poster Session


Join this session to showcase your research and begin those all-important conversations to improve age-related disease outcomes!

4:30 pm The First Longevity Drugs Will Be Multi-Morbidity Preventative Medicines


  • Advancing single hypothesis breakthroughs in aging research
  • Innovations: CR and exercise mimetics – the lowest hanging fruit in longevity biotech
  • Moonshots: Revealing the next generation of longevity targets developed

Establishing a Clear Consensus on Preclinical & Clinical Trial Design to Supercharge Therapeutics to Patients in Need

5:00 pm Oligo-Senotherapeutics for Improving Health Span


  • Dysregulation of RNA processing is a new and druggable hallmark of aging
  • Identification of traction points for the attenuation of senescence phenotypes
  • Unravelling a platform technology that can be applied for the treatment of any disease driven by senescence including eye, lungs, and joints

5:30 pm Multiple Rings to Take Them All: Targeting Cellular Senescence Heterogeneity Across Age-Related Diseases

  • Marco Quarta Chief Executive Officer & Co-Founder, Rubedo Life Sciences


  • Senolytics is a powerful therapeutic opportunity to treat age-related chronic conditions
  • An analogy with cancer cells: Cellular senescence is pleiotropic and characterised by a high degree of heterogeneity
  • Not all states of cellular senescence are relevant therapeutic targets
  • Introducing Alembic: a computational single-cell multi-omics platform developed to elucidate the heterogeneity between cell types and cell states for
    novel first-in-class drug discovery

6:00 pm Mapping Translational Ability: How to Approach Clinical Trials in a Multi-Factorial Disorder?


  • Linking models to indication selection and clinical endpoints
  • Leveraging new, emerging technologies in the aging research field
  • Early biomarker discovery efforts enable clinical translation


6:30 pm Chair’s Closing Remarks